Global Blood Therapeutics Current Ratio 2014-2021 | GBT

Global Blood Therapeutics current ratio from 2014 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Global Blood Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.53B $0.07B 7.22
2021-03-31 $0.56B $0.06B 9.47
2020-12-31 $0.63B $0.08B 8.00
2020-09-30 $0.60B $0.08B 7.63
2020-06-30 $0.59B $0.07B 8.56
2020-03-31 $0.56B $0.06B 9.07
2019-12-31 $0.63B $0.07B 8.79
2019-09-30 $0.62B $0.04B 14.95
2019-06-30 $0.67B $0.04B 16.79
2019-03-31 $0.47B $0.03B 14.51
2018-12-31 $0.49B $0.03B 14.38
2018-09-30 $0.39B $0.03B 14.57
2018-06-30 $0.47B $0.02B 22.06
2018-03-31 $0.55B $0.02B 23.12
2017-12-31 $0.32B $0.03B 12.35
2017-09-30 $0.23B $0.02B 14.05
2017-06-30 $0.24B $0.02B 13.70
2017-03-31 $0.25B $0.02B 16.84
2016-12-31 $0.15B $0.02B 9.65
2016-09-30 $0.22B $0.01B 16.82
2016-06-30 $0.23B $0.01B 17.79
2016-03-31 $0.14B $0.01B 11.88
2015-12-31 $0.15B $0.01B 15.55
2015-09-30 $0.16B $0.01B 24.45
2015-06-30 $0.04B $0.01B 8.10
2015-03-31 $0.05B $0.00B 11.01
2014-12-31 $0.05B $0.00B 21.13
2014-09-30 $0.00B 0.00
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.00B $0.00B 0.99
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.631B $0.124B
Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71